Systematic Screening for Primary Immunodeficiencies in Patients Hospitalized for Severe Infections in Intensive Care.

Primary Immunodeficiency Clinical Trial

— DIPREA  

Official title:

Systematic Screening for Primary Immunodeficiencies in Patients Hospitalized for Severe Infections in Intensive Care : DIPREA

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04356053
• Other study ID #: RECHMPL20_0199
• Status: Recruiting
• Start date: April 1, 2020
• Est. completion date: December 30, 2021

Study information

• Verified date: October 2021
• Source: University Hospital, Montpellier
• Contact: Eric JEZIORSKI
• Phone: 04 67 33 57 98
• Email: e-jeziorski[@]chu-montpellier.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Currently about 90 cases of infection in children are reported every year in pediatric intensive care, a disease considered to be the main cause of hospitalization of children. 16% of invasive pneumococcal infections are linked to a genetic abnormality in immunity. Herpetic encephalitis has become a model of genetic infectious disease, with new mutations identified in the TLR3 pathway. Severe infections are no longer the result of chance and can be the way to reveal a primary immune deficiency. In this context, the investigators propose to evaluate the incidence of hereditary immune deficiency after a systematic immunological screening in children admitted for a severe infection in pediatric intensive care unit (ICU).

Description:

Severe infection requiring admission in intensive care unit (ICU) are not so rare. A retrospective pilot study conducted at Montpellier University Hospital Center (UHC) between 2013 and 2015 showed that 19.7% of the pediatric ICU admissions were related to a severe infection. An isolated severe infectious episode could be related to a hereditary immune deficiency (HID), even though there are no history of recurrent clinical signs and biological stigmata. For example, Gaschignard and colleagues considered that 16% of the invasive pneumococcal infections are related to a genetic defect of immunity (doi: 10.1093/cid/ciu274). Growing evidence has shown that severe infectious diseases occurring in childhood are attributed to inborn errors of immunity (doi: 10.1073/pnas.1521651112). While the nosology of severe infections has strong links to inherited immune deficiency that are rare diseases affecting less than 1 birth / 5000, there are no prospective studies that assessed the incidence of primary immune deficiencies in children who presented a severe infection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: December 30, 2021
• Est. primary completion date: December 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month to 16 Years

Eligibility

Inclusion criteria:

• Subject aged 1 month to 16 years.

• Admission in pediatric ICU for more than 24h.

• Documented severe infection (bacterial, viral, fungal).

• Child benefiting from a social security scheme.

• Collection of parental consent / legal representatives.

Exclusion criteria:

• Prematurity (gestational age <37 weeks of gestation) up to 6 months of age.

• Undocumented severe infections.

• Children entered for isolated RSV bronchiolitis, with no other infectious related complications.

• Previous comorbidity explaining the infection and/or the stay in intensive care / continuous care: known primary or secondary immunodeficiency; burned; risk factors for status epilepticus (encephalopathy, known epilepsy, head trauma), pneumonia or asthma (swallowing disorders, tracheotomy, chronic pulmonary pathology, asthma), meningitis (cochlear implants, breccia, neuromeningeal material), deep infection (implanted material, recent surgery), cardiovascular decompensation.

• Any other chronic pathology favoring an infection

• Impossibility to obtain the consent of parents / legal representatives.

Related Conditions & MeSH terms

• Immunologic Deficiency Syndromes
• Infections
• Primary Immunodeficiency
• Primary Immunodeficiency Diseases

Locations

Country	Name	City	State
France	Uhmontpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	duration of hospitalization	Compare the duration of hospitalization enter the group treated by alone antibiotic and the group treated by antibiotic and surgical drainage.	1 day
Primary	Immunological abnormalities	Immunological abnormalities : based on the screening test	1 day
Secondary	Diagnosis of primary immunodeficiency	Diagnosis of primary immunodeficiency	1 day